Acid Reflux
Return to Library
|
Free Acid Reflux Articles |
|
|
|
|
New genetics & genomics data have been reported by researchers at Hamamatsu University
2009 JUL 27 - (NewsRx.com) -- "Maintenance therapy of gastroesophageal reflux disease (GERD) is usually performed with a low dose of a proton-pump inhibitor (PPI). Because PPIs are metabolized by CYP2C19 in the liver, we investigated whether a patient's CYP2C19 genotype was associated with symptomatic recurrence of GERD during maintenance therapy with a low dose of a PPI," scientists in Hamamatsu, Japan report. "We enrolled 124 patients with erosive GERD whose esophageal mucosal breaks were endoscopically proven to be cured after treatment with lansoprazole 30 mg/day for 8 weeks. When reflux symptoms occurred less than once per week, the dose of lansoprazole was decreased to 15 mg/day, but if symptoms then occurred more than once per week, it was restored to 30 mg/day. CYP2C19 genotypes were classified as rapid metabolizer (RM), intermediate metabolizer (IM) or poor metabolizer (PM). In 18 of 54 RMs, 28 of 56 IMs, and 8 of 14 PMs, the maintenance dose of lansoprazole was decreased to 15 mg/day, but in 16 (88.9%), 22 (78.6%), and 4 (50%), respectively, there was symptomatic recurrence of GERD and the dose was restored to 30 mg/day. The hazard ratios of symptomatic recurrence of GERD in IMs and PMs compared with RMs were 0.40 (95%CI: 0.19-0.87, P = 0.021) and 0.19 (95%CI: 0.05-0.69, P = 0.011). When the dose of lansoprazole is decreased, the RM genotype of CYP2C19 appears to be a risk factor for symptomatic recurrence of GERD," wrote T. Furuta and colleagues, Hamamatsu University. The researchers concluded: "The CYP2C19 genotyping test would be useful for determining the optimal dose of a PPI for maintenance therapy of GERD.." Furuta and colleagues published their study in European Journal of Clinical Pharmacology (CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. European Journal of Clinical Pharmacology, 2009;65(7):693-698). For additional information, contact T. Furuta, Hamamatsu University School Medical, Clinic Research Center, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan. The publisher's contact information for the European Journal of Clinical Pharmacology is: Springer, 233 Spring St., New York, NY 10013, USA. Keywords: Japan, Hamamatsu, Genetics & Genomics, Acid Reflux, Clinical Pharmacology, Drugs, Gastroenterology, Gastroesophageal Reflux Disease, Genotyping, Lansoprazole, Pharmaceuticals, Pharmacology, Therapies, Therapy, Treatment, Hamamatsu University. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
